Kornimate/medical-research-clean huggingface dataset:
cervical stabilization exercises on respiratory strength in chronic neck pain

Conditions: Neck Pain

Summary: this project was a randomized control trial conducted to check the effects of cervical stabilization exercises on respiratory strength in chronic neck pain patients with forward head posture, duration of study was of 6 months, convenient sampling was done, subject following eligibility criteria from jinnah hospital lahore, were randomly allocated in two groups via lottery method, baseline assessment was done, group a participants were given baseline treatment protocol for 4 weeks which included 3 sessions per week. heating pad applied for 15 min and tens (transcutaneous electric nerve stimulation) for 10 min. after that cervical isometric exercises performed in sitting (10sec hold, 10 to 15 reps). group b was experimental group and participants were given baseline treatment in addition to cervical stabilization exercises for 4 weeks which included 3 sessions per week. the baseline measurement was taken on day one for numeric pain rating scale (nrps) and neck disability index (ndi). forward head posture assessed by measuring cranio vertebral angle (cva). respiratory muscle strengths measured by spirometer and sbc (single breath count). all the measurements repeated at the end of fourth week. data was analyzed by using spss version 20.

extensive usage of electronic gadgets in today's life leads to the musculoskeletal problems among which neck pain is the most common problem reported to physicians, orthopedics and physical therapists. even before reporting to clinics there is long history of using over the counter pain killers. pain avoidance behaviors let the cervical spine stiff so much that a clinician help is sought. there is huge literature regarding the management of chronic neck pain and yet after the decades of research there are gaps in treatment options. in modern age of health care, it is common goal of every healthcare to make patient self-sufficient as early as possible. the self-care models have tremendous advantages. the current study has compared the effects of cervical stabilization exercises and isometric exercises. the current study was novel in a way that there is limited literature about treating chronic neck pain patients with effects of physiotherapy on respiratory strength in improving forward head posture. all the methods were employed to see if they improve ranges along with accompanying pain and disability.

Eligibility criteria:
inclusion criteria: * patients with chronic neck pain for more than 3 months. * mild neck disability (ndi score 5-15) exclusion criteria: * neck pain secondary to trauma * deformities of thoracic region or vertebral column * history of any thoracic or vertebral column surgery. * history of smoking * patients with any other serious pathology/red flags

Keywords: ndi, nprs, cva, sbc
tocolysis in prevention of preterm labor

Conditions: Preterm Labor Without Delivery

Summary: preterm birth is defined as birth before 37 completed weeks of gestation .it occurs in 11.1%of birth globally affecting an estimated 14.9 million babies every year . it is generally accepted that approximately 65%-70%of preterm births are spontaneous,40%-45% of them due to spontaneous preterm labor and 25%-30%following preterm rupture of membranes.preterm birth represents the single largest cause of morbidity and mortality for newborn and is estimated for 29%of deaths in the first four weeks of life and also is estimated for of major cause of morbidity for pregnant women . tocolytic agents include a wide range of drugs that can slow or suppress uterine contractions . tocolytic are considered advantages in spontaneous preterm labor to : (a) allow time for the fetus to mature ,potentially avoiding deleterious effects of pre-maturity . (b)allow time for antenatal corticosteroids to be administered and have clinical effect. (c) allow time for intrauterine transfer to higher-care center where neonatal intensive care facilities are available . the ideal tocolytic agent should be effective , easy to administer , without significant material ,fetal or neonatal side effects and permit time for antenatal corticosteroids to be administered and take effect . a variety of tocolytic treatments have been used to inhibit uterine activity in women in spontaneous preterm labor , including betamimetics , calcium channel blockers , magnesium sulfate , prostaglandin inhibitors and oxytocin receptor antagonists however there is considerable global variation in types , doses and regimens of tocolytic agents uses to manage preterm labor . a comparison study between ritodrine, magnesium sulfate and nifedipine in terms of effect and morbidity will be conducted.


Eligibility criteria:
inclusion criteria: * . gestational age between 24-37weeks * symptoms such as low backache , cramping ,pelvic pressure, excessive vaginal discharge and vaginal spotting . * regular uterine contractions at least of 30 seconds duration at a rate of more than 4/30 minutes * cervical changes dilatation less than 3cm,effacement lessthan50%. * intact membranes. exclusion criteria * active vaginal bleeding and placental abruption. * chorioamnionitis and intrauterine infection * fetal conditions : fetal death or distress, lethal congenital or chromosomal abnormalities and intra uterine growth restriction * maternal conditions indicate that pregnancy shouldn't be continued: eclampsia , severe preeclampsia and cardiac diseases * drug specific contraindications(contraindication of tocolysis)
ticagrelor for pci post thrombolysis

Conditions: Acute Myocardial Infarction

Summary: ticagrelor is a first line therapy along with aspirin for patients undergoing primary pci for stemi. however, many patients are still treated with fibrinolytic therapy and the safety and efficacy of ticagrelor has not been investigated in this patients population. the present study is proposed to study the safety and efficacy of ticagrelor in patients undergoing pci post fibrinolytic therapy for stemi.

the newer antiplatelet agents such as ticagrelor have demonstrated superiority to clopidogrel in patients presenting with acute coronary syndrome (acs). at present ticagrelor remains a first line therapy as an adjunct to aspirin for patients undergoing primary pci for stemi for reducing major adverse events. however, the safety and efficacy of ticagrelor has not been investigated in patients with stemi post fibrinolysis. ticagrelor results in significantly higher platelet inhibition than aspirin or clopidogrel and may expose patients to an increased risk of bleeding if administered post thrombolysis. however, fibrinolytic therapy itself results in a prothrombotic milieu with greater activation of platelets, a condition that can be balanced with addition of stronger antiplatelet agents. similar concerns were initially reflected for clopidogrel as an adjunct to fibrinolytic therapy but were later proven to be unsubstantiated. in fact, adjunct administration of clopidogrel to fibrinolytic therapy reduces major adverse events as shown by multiple studies and has become the standard of care recommended by guidelines. the present study is proposed to study the safety and efficacy of ticagrelor in patients undergoing pci post fibrinolytic therapy for stemi.

Eligibility criteria:
inclusion criteria: 1. age 18 years and over. 2. planned pci between 4-24 hours after administration of fibrinolytic therapy for stemi. 3. treatment with aspirin and clopidogrel as an adjunct to fibrinolytic therapy. 4. informed written consent. exclusion criteria: 1. atrial fibrillation or need for systemic anticoagulation therapy. 2. prior pci or coronary artery bypass grafting during past 3 months. 3. active bleeding or high risk of bleeding based upon clinical assessment. 4. known severe liver or renal disease or patient requiring dialysis. 5. concomitant oral or iv therapy with strong cytochrome (cyp3a) inhibitors which cannot be stopped. 6. contraindication to ticagrelor or clopidogrel. 7. planned surgery during the study period. 8. any of the following in the absence of a functioning implanted pacemaker: sick sinus syndrome, 2nd or 3rd degree avb, documented syncope of suspected bradycardic origin. 9. known clinically important thrombocytopenia or anemia. 10. known pregnancy or lactation. 11. condition which may either put the patient at risk or influence the result of the study. 12. previous randomization in this setfast study. 13. participation in another clinical study with an investigational product or device study over the past 30 days.

Keywords: fibrinolytic therapy stenting platelet activity
model-based image reconstruction for x-ray ct in lung imaging

Conditions: Lung Diseases

Summary: to develop a computer program that will improve ct image quality and decrease the amount of x-ray radiation that future patients may be exposed to when they have a ct examination.

we will be asking patients for their permission to save and use the sinogram from their ct scan. the sinogram will be de-identified and sent to an archive system for storage. it will be exported to a computer for processing using mbir (model based iterative reconstruction). mbir (model based iterative reconstruction) is a new method being developed to process ct sinograms. the newly reconstructed images will be reviewed by experts to determine if they are as readable and accurate as ct images created with the software that is currently being used. sinogram data and the reconstructed images will be shared with collaborating researchers at general electric global research.

Eligibility criteria:
inclusion criteria: 1. 18 years of age and older 2. no medical or psychiatric condition precluding informed consent - exclusion criteria: 1. inability to lie flat on the back with arms raised over the head for 30min. 2. metallic implants or metallic devices in the chest or back. 3. participation in other research trials involving ionizing radiation
hydroxyurea optimization through precision study

Conditions: Sickle Cell Disease; Sickle Cell Anemia

Summary: hydroxyurea optimization through precision study (hops) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with sca. the primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. patients will be recruited from the pediatric sickle cell clinic at cincinnati children's hospital medical center and from additional pediatric sickle cell centers within the united states.

the trial will recruit patients who have decided to initiate hydroxyurea therapy. all participants will have pharmacokinetics studies performed at baseline, following a 20 mg/kg oral dose of hydroxyurea. pharmacokinetic sampling will use a sparse sampling approach, requiring collection of blood at 3 time points (15 minutes, 60 minutes, 180 minutes) following the hydroxyurea dose. enrolled participants will be randomized to receive either hydroxyurea using a starting dose of 20 mg/kg/day (standard arm) or a personalized pk-guided dose (alternative arm) to target an area under the curve (auc) of 115 mg\*h/l based to approximate hydroxyurea exposure seen when patients are escalated to maximum tolerated dose (mtd). following randomization and selection of the initial dose, participants in both arms will follow the same procedures of laboratory medication holds for hematological toxicity. the primary endpoint is fetal hemoglobin (hbf) six months following the initiation of hydroxyurea therapy with the hypothesis that participants starting with a pk-guided dose will achieve hbf at least 5% greater than those starting with a 20 mg/kg dose. based upon the estimated number of new hydroxyurea starts at each site, it is anticipated that it will take 24 months to enroll the 116 participants required to achieve sufficient power to assess the primary endpoint. the study will conclude for each participant 12 months following hydroxyurea initiation.

Eligibility criteria:
inclusion criteria: * diagnosis of sickle cell anemia (hbss, hbsd, hbs/β0-thalassemia, or similarly severe sca genotype) * age 6 months to 21 years at the time of enrollment * clinical decision by patient, family, and healthcare providers to initiate hydroxyurea therapy exclusion criteria: * current treatment with chronic, monthly blood transfusions or erythrocytapheresis * treatment with hydroxyurea within the past 3 months * hemoglobin sc disease, hbs/β+-thalassemia * current treatment with other investigational sickle cell medications * current known pregnancy or lactation

Keywords: hydroxyurea hbss hbsd treat
a multicenter, randomized, double-blind, placebo-controlled parallel-group phase 2 clinical trial to evaluate the efficacy and safety of xh-s004 tablets in patients with non-cystic fibrosis bronchiectasis

Conditions: Non-Cystic Fibrosis Bronchiectasis

Summary: the purpose of this study is to find out if xh-s004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.

this study is a multicenter, double-blind, placebo-controlled, parallel-group study conducted in china, aimed at evaluating the efficacy, safety and tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of xh-s004 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (ncfbe). this study plans to enroll 231 patients with bronchiectasis. patients who sign the informed consent form will be screened according to the enrollment criteria, and randomly divided into 3 groups. participants in groups 1 and 2 will receive different doses of xh-s004. participants in group 3 will receive placebo.

Eligibility criteria:
inclusion criteria: 1. understand the procedures and methods of this trial and sign a written informed consent form; 2. male or female paticipants aged 18-85 years (inclusive) ; 3. chest hrct shows bronchiectasis affecting one or more lobes, and the condition is clinically diagnosed as non-cystic fibrosis bronchiectasis (clinical manifestations include chronic cough, significant productive cough, and/or intermittent hemoptysis, with or without varying degrees of polypnoea and other symptoms); 4. based on medical history and the determination of the investigator , participants have at least 2 documented pulmonary exacerbations in the past 12 months before screening; 5. are current sputum producers with a history of chronic expectoration and able to provide a spontaneous sputum sample at screening visit (as described by the patient) ; 6. the body mass index (bmi) is ≥18 kg/m2 at screening; 7. participants must ensure and agree that from 28 days prior to signing the informed consent form to 28 days after the final administration, women of childbearing potential, male participants, and their partners will use effective contraception methods other than oral drugs (e.g., condoms or intra-uterine contraceptive devices) and will not donate sperm or eggs during this period exclusion criteria: 1. have a primary diagnosis of chronic obstructive pulmonary disease (copd) or asthma 2. have bronchiectasis due to cystic fibrosis (cf), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency 3. are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis 4. have any acute infections, (including respiratory infections) 5. patients who have previously received therapy with dpp1 inhibitors of the same class

Keywords: bronchiectasis active neutrophil elastase fibrosis
fenofibrate bioequivalence study (0767-031)

Conditions: Dyslipidemia

Summary: this study will determine definitive bioequivalence of the united states (u.s.) and united kingdom (uk) formulations of fenofibrate following administration of single doses in healthy adult subjects.


Eligibility criteria:
inclusion criteria: * subject is in good health * subject is willing to follow all study guidelines exclusion criteria: * subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study or make participation unsafe * female subject is receiving oral contraceptives or hormone replacement therapy
study to evaluate the efficacy of adalimumab in patients with erosive osteoarthritis of the interphalangeal finger joints

Conditions: Erosive Osteo-Arthritis

Summary: patients will be randomized into two groups (1/1) during one year: * 40 mg adalimumab subcutaneously (sc) every other week * placebo the effect on x-rays and clinical parameters will be evaluated.


Eligibility criteria:
inclusion criteria: * clear erosive image on x-ray of at least one interphalangeal finger joint
90-day cobalt supplementation study to investigate the cobalt body burden in ten healthy adult volunteers

Conditions: Cobalt Biokinetics; Safety of Cobalt Dietary Supplementation

Summary: the purpose of this study is to investigate steady-state cobalt levels following dietary supplementation for 90 days with 1 mg cobalt/day (as cobalt chloride in solution) in healthy adult volunteers.

over the counter cobalt (co) dietary supplements are available for sale in the united states, but little is known regarding their clinical effects and biokinetic distribution and body burden with long-term use. this study assessed blood kinetics, steady-state levels, biochemical responses, and clinical effects in five adult males and five adult females who voluntarily ingested approximately 1.0 mg co/day of a commercially available co supplement over a three month period. volunteers were instructed to take the co-dietary supplement in the morning according to the manufacturer's label. blood samples were collected and analyzed for a number of biochemical parameters before, during, and after dosing. hearing, vision, cardiac, and neurological functions were also assessed in volunteers before, during, and after dosing.

Eligibility criteria:
inclusion criteria: * subject ≥ 18 years old. * subject able to understand and willing to sign a written informed consent form for the study. exclusion criteria: * subject is unwilling to discontinue current multivitamins or other types of dietary supplements while on study * subject has a documented history of an allergy to cobalt * subject has a documented history of severe cardiac problems (e.g., congestive heart failure, myocardial ischemia within past 12 months, cardiomyopathy) * subject has a documented history of thyroid, kidney, or liver disease * subject has insulin-dependent diabetes * subject has a concurrent illness or personal stressor which in the opinion of the investigator may interfere with the subject's ability to perform the study's requirements. * subject has a total joint replacement (e.g., knee, hip, shoulder) * subject is pregnant or breastfeeding * subject is unwilling to follow protocol requirements * subject weight is less than 45 kg

Keywords: cobalt dietary supplements hematological thyroid
multimodalitic imaging in the n-stage of lung cancer

Conditions: Neoplasm of Lung

Summary: this study aims to evaluate the diagnostic efficacy and differences between 18f-fdg pet/ct and mr stir sequences combined with ebus-tbna, 18f-fdg pet/ct combined with ebus-tbna, and mr stir sequences combined with ebus-tbna - three types of multimodal imaging for assessing nsclc n-stage, in order to select the best assessment protocol to guide treatment decisions and prognostic assessments.


Eligibility criteria:
inclusion criteria: * biopsy pathologically confirmed nsclc, or clinically highly suspicious nsclc (assessed as highly suspicious by the mdt team of this study); * n1, n2, or n3 confined to the mediastinum and hilum, as assessed by imaging; * proposed systematic lymph node dissection without any treatment; * appropriate laboratory tests (serum tumor markers); * all examination intervals ≤ 4 weeks; * kps score ≥ 50 (ecog/who equivalent); * aged \> 18 years; 8. patients can fully understand and voluntarily participate in this trial and sign the informed consent; the examination can be completed independently. exclusion criteria: * contraindication to ebus-tbna operation; * presence or history of other malignancies within 10 years; * inability to understand the examination procedure or to cooperate.

Keywords: 18f-fdg pet/ct neoplasm of lung ebus-tbna mr stir nsclc n-stage
inducible laryngeal obstruction in severe asthma in severe asthma

Conditions: Asthma Chronic; Vocal Cord Dysfunction

Summary: the first part will be a comparative cross-sectional study to identify the frequency of ilo and other comorbidites among participants with asthma compared to a group of reference subjects without asthma, matched for age- and gender and race. the second part will be a longitudinally observational study study following participants for one year after the cross-sectional study. the maat-scores ilo-symptoms and asthma-outcomes longitudinally will be evaluated, .

inducible laryngeal obstruction (ilo) is characterized by inappropriate closure of the structures of the larynx causing reduced airflow. the symptoms are breathing difficulties that resemble those seen in asthmatic patients, such as dyspnea, coughing and stridor. ilo may be diagnosed by the continuous laryngoscopy during exercise test (cle-test), where the larynx is visualized live on video as the patient runs to exhaustion on a treadmill whilst having a laryngoscope placed through the nose. the prevalence of ilo in asthmatic patients will be assesed by preforming a cle-test twice in all participants at baseline and again after one year. participant will be given visual feedback and instructed in breathing techniques. others common comorbidities will be assessed by questionnaires and clinical interview. all patients with asthma will have a respiratory polygraph recording. changes in ilo-symptoms and asthma-symptoms and outcomes will be assessed after 1 year.

Eligibility criteria:
inclusion criteria: * patients with severe asthma (gina 5) * patients with mild-moderate well-treated asthma (gina step 1-4) * agroup of age- and gender matched control subjects without asthma also aged 18- 70. * the patients must have had a stable disease the last one month before performing the cle-test exclusion criteria: * no have underlying neurologic disease. * no known cancer in the lung-head-neck * no known vocal cord pathology. * no history of life-threatening asthma required hospitalization.

Keywords: inducible laryngeal dysfunction, severe asthma,